The Truth about Lipid Effects of the Thiazolidinediones
- 1 September 2005
- journal article
- research article
- Published by Mary Ann Liebert Inc in Metabolic Syndrome and Related Disorders
- Vol. 3 (3), 194-197
- https://doi.org/10.1089/met.2005.3.194
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- A Comparison of Lipid and Glycemic Effects of Pioglitazone and Rosiglitazone in Patients With Type 2 Diabetes and DyslipidemiaDiabetes Care, 2005
- The Dyslipidemia of Diabetes Mellitus: Giving Triglycerides and High-Density Lipoprotein Cholesterol a Higher Priority?Endocrinology and Metabolism Clinics of North America, 2005
- A Meta-analysis Comparing the Effect of Thiazolidinediones on Cardiovascular Risk FactorsArchives of Internal Medicine, 2004
- The effects of oral anti‐hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetesDiabetes, Obesity and Metabolism, 2004
- Thiazolidinediones and Blood Lipids in Type 2 DiabetesArteriosclerosis, Thrombosis, and Vascular Biology, 2003
- Metabolic SyndromeJournal of the American College of Cardiology, 2002
- Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With PioglitazoneDiabetes Care, 2001
- Nonhypoglycemic Effects of ThiazolidinedionesAnnals of Internal Medicine, 2001
- Insulin resistance and cardiovascular diseaseJCI Insight, 2000
- Insulin Resistance: A Multifaceted Syndrome Responsible for NIDDM, Obesity, Hypertension, Dyslipidemia, and Atherosclerotic Cardiovascular DiseaseDiabetes Care, 1991